Optimal control analysis of combined anti-angiogenic and tumor immunotherapy

The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells,...

Full description

Bibliographic Details
Main Author: Anuraag Bukkuri
Format: Article
Language:English
Published: Ptolemy Scientific Research Press 2019-11-01
Series:Open Journal of Mathematical Sciences
Subjects:
Online Access:https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/
id doaj-4750eb1547024d0a9caf13e0f9f28a80
record_format Article
spelling doaj-4750eb1547024d0a9caf13e0f9f28a802020-11-25T02:23:40ZengPtolemy Scientific Research PressOpen Journal of Mathematical Sciences2616-49062523-02122019-11-013134935710.30538/oms2019.0078Optimal control analysis of combined anti-angiogenic and tumor immunotherapyAnuraag Bukkuri0Department of Mathematics, University of Minnesota, Minneapolis, MN 55455, USA.The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells, and anti-angiogenesis. Existence, uniqueness, and characterization of optimal treatment profiles that minimize the tumor and drug usage, while maintaining healthy levels of effector and host cells are determined. A theoretical analysis is performed to characterize the optimal control. Numerical simulations are performed to illustrate optimal control profiles for a variety of different patients, each leading to different treatment protocols.https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/optimal controlimmunotherapyanti-angiogenesis
collection DOAJ
language English
format Article
sources DOAJ
author Anuraag Bukkuri
spellingShingle Anuraag Bukkuri
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
Open Journal of Mathematical Sciences
optimal control
immunotherapy
anti-angiogenesis
author_facet Anuraag Bukkuri
author_sort Anuraag Bukkuri
title Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
title_short Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
title_full Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
title_fullStr Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
title_full_unstemmed Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
title_sort optimal control analysis of combined anti-angiogenic and tumor immunotherapy
publisher Ptolemy Scientific Research Press
series Open Journal of Mathematical Sciences
issn 2616-4906
2523-0212
publishDate 2019-11-01
description The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells, and anti-angiogenesis. Existence, uniqueness, and characterization of optimal treatment profiles that minimize the tumor and drug usage, while maintaining healthy levels of effector and host cells are determined. A theoretical analysis is performed to characterize the optimal control. Numerical simulations are performed to illustrate optimal control profiles for a variety of different patients, each leading to different treatment protocols.
topic optimal control
immunotherapy
anti-angiogenesis
url https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/
work_keys_str_mv AT anuraagbukkuri optimalcontrolanalysisofcombinedantiangiogenicandtumorimmunotherapy
_version_ 1724857989132713984